[Translation into French and republication of: "Central venous catheter associated upper extremity deep vein thrombosis in cancer patients: Diagnosis and therapeutic management"].
Traduction et republication de : « Thrombose veineuse profonde du membre supérieur associée à un cathéter veineux central chez les patients cancéreux : diagnostic et prise en charge thérapeutique ».
Cancer
Cathéter veineux central
Central venous catheter
Deep vein thrombosis
Maladie thromboembolique veineuse
Thrombose veineuse profonde
Venous thromboembolism
Journal
La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
received:
17
11
2023
accepted:
17
11
2023
medline:
2
6
2024
pubmed:
2
6
2024
entrez:
1
6
2024
Statut:
aheadofprint
Résumé
Catheter-related thrombosis (CRT) is a relatively frequent and potentially fatal complication arising in patients with cancer who require a central catheter placement for intravenous treatment. In everyday practice, CRT remains a challenge for management; despite its frequency and its negative clinical impact, few data are available concerning diagnosis and treatment of CRT. In particular, no diagnostic studies or clinical trials have been published that included exclusively patients with cancer and a central venous catheter (CVC). For this reason, many questions regarding optimal management of CRT remain unanswered. Due to the paucity of high-grade evidence regarding CRT in cancer patients, guidelines are derived from upper extremity DVT studies for diagnosis, and from those for lower limb DVT for treatment. This article addresses the issues of diagnosis and management of CRT through a review of the available literature and makes a number of proposals based on the available evidence. In symptomatic patients, venous ultrasound is the most appropriate choice for first-line diagnostic imaging of CRT because it is noninvasive, and its diagnostic performance is high (which is not the case in asymptomatic patients). In the absence of direct comparative clinical trials, we suggest treating patients with CRT with a therapeutic dose of either a LMWH or a direct oral factor Xa inhibitor, with or without a loading dose. These anticoagulants should be given for a total of at least 3 months, including at least 1 month after catheter removal following initiation of therapy.
Identifiants
pubmed: 38823999
pii: S0248-8663(24)00580-0
doi: 10.1016/j.revmed.2024.05.018
pii:
doi:
Types de publication
English Abstract
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Investigateurs
Y Benhamou
(Y)
A Benmaziane
(A)
L Bertoletti
(L)
V Bichon
(V)
C Bozec
(C)
A Cohen
(A)
F Couturaud
(F)
P Debourdeau
(P)
P Dielenseger
(P)
É Douriez
(É)
A Élias
(A)
O Espitia
(O)
C Frère
(C)
Y Gaboreau
(Y)
P Gendron
(P)
P Girard
(P)
O Hanon
(O)
A Idbaih
(A)
S Laporte
(S)
I Mahé
(I)
D Mayeur
(D)
P Mismetti
(P)
F Moustafa
(F)
G Pernod
(G)
P-M Roy
(PM)
M-È Rouge Bugat
(MÈ)
O Sanchez
(O)
J Schmidt
(J)
F Scotté
(F)
M-A Sevestre
(MA)
Informations de copyright
Copyright © 2024. Published by Elsevier Masson SAS.